We found that low levels of MACROH2A2 transcription were associated with shorter overall survival in the high-grade glioma cohort collected by TCGA (log-rank p = 0.035; Fig. 1a) and in IDH-wildtype GBM patients in the Gravendeel cohort (log-rank p = 0.0085; Fig. 1b). This evidence concerns the gene MACROH2A2 and central nervous system cancer.